Discover Magazine on MSN2d
Triggering Cancer Cells To Self-Destruct Could Help Tumors to ShrinkNatural "off switch" could slow or even reverse the growth of aggressive tumors.
B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.
The Brighterside of News on MSN6d
Researchers discovered how to turn on cancer’s 'kill switch'Cells have a natural editing system that allows them to rearrange genetic instructions to create different proteins from the ...
Scientists reveal how cancer cells manipulate RNA splicing, increasing tumor growth. A new study introduces antisense ...
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...
Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...
Exons are coding sections of an RNA transcript, or the DNA encoding it, that are translated into protein. Exons can be separated by intervening sections of DNA that do not code for proteins, known ...
Researchers have discovered that cancer cells suppress 'poison exons' -- genetic elements that act as an off switch for protein production -- in a key gene called TRA2 , promoting tumor growth. By ...
Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...
Avidity Biosciences (RNA) announced positive del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular ...
Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback